GST Council Likely To Give Relief On A Slew Of Cancer Drugs: Sources to TimsyJaipuria

📌Tax on Trastuzumab Deruxtecan, Osimertinib & Durvalumab can be cut to 5% from 12%
📌Fitment panel’s recommendations based on proposal shared by Health Ministry

📌Alert: Manufacturers of these #CancerDrugs are #Abbott, #ZydusLife, #Alkem, #RelianceLife, #Cipla, #Mylan & #Biocon
📌Alert: 54th #GSTCouncil to meet on September 9 in Delhi